https://carolinaurologicresearchcenter.com/wp-content/uploads/9.14-Pfizer.jpg250300CURC/wp-content/uploads/logo-1.pngCURC2017-09-14 09:39:082017-09-14 09:40:45Pfizer and astellas announce positive top line results from phase 3 prosper trial of xtandi enzalutamide in patients with non metastatic castration resistant prostate cancer. With Dr. Neal Shore
Recombinant Adenovirus Interferon-α With Syn3 in BCG-Refractory or Relapsed...